Research Article
BibTex RIS Cite

Year 2024, Volume: 37 Issue: 1, 67 - 71, 28.01.2024

Hatice Çalışkan Mehmet Yaşar Dilek Yazıcı Oğuzhan Deyneli

https://doi.org/10.5472/marumj.1381672

Abstract

References

  • Powers, AC. Diabetes Mellitus. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison’s Principle of Internal Medicine. New York: The McGraw-Hill Companies, 2012:2968-69.
  • Fleir JS. Hormone resistance in diabetes and obesity: insulin, Leptin, and FGF21. Yale J Biol Med.Yale 2012; 85:405-14.
  • Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57:1246- 53. doi: 10.2337/db07-1476.
  • Li H, Bao Y, Xu A, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gammaglutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009; 94:2151-6. doi: 10.1210/jc.2008-2331
  • Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010; 53:934- 40. Doi: 10.1016/j.jhep.2010.05.018
  • Xiao Y, Xu A, Law LS, et al. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J Clin Endocrinol Metab 2012; 97:54-8. doi: 10.1210/jc.2011-1930
  • Zibar K, Blaslov K, Bulum T, Ćuća JK, Smirčić-Duvnjak L. Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls. Endocrine 2015; 48:848-55. doi: 10.1007/ s12020.014.0413-9
  • Yamasaki Y, Kawamori R, Matsushima H, et al. Atherosclerosis in carotid artery of young IDDM patients monitored by ultrasound high resolution B-mode imaging. Diabetes 1994; 43:634-9. doi: 10.2337/diab.43.5.634
  • Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994;236:567-73. doi: 10.1111/j.1365-2796.1994.tb00847.x.
  • Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE. Hypoadiponectimia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930-35. doi: 10.1210/ jcem.86.5.7463.
  • Imagava A, Funahashi T, Nakamura T, et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 2002;25:1665-6. doi: 10.2337/diacare.25.9.1665
  • Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23:85-9. doi: 10.1161/01. atv.000.004.8856.22331.50.
  • Stitt AW, Jenkins AJ, Cooper ME. Advanced glycation end products and diabetic complications. Informa Healthcare 2002;11:1205-23. doi: 10.1117/1.JBO.22.8.085003
  • Wautier MP, Massin P, Guillausseau PJ, et al. N(carboxymethyl) lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes and Metab 2003; 29:44–52. doi: 10.1016/s1262-3636(07)70006-x.
  • Taniguchi H, Nirengi S, Ishihara K, Sakane N. Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus. PLoS One 2022;17:e0263774. doi: 10.1371/journal.pone.0263774.
  • Zhang J, Weng W, Wang K, Lu X, Cai L, Sun J. The role of FGF21 in type 1 diabetes and its complications. Int J Biol Sci 2018;14:1000-11. doi: 10.7150/ijbs.25026.
  • Bayir O, Korkmaz HA, Dizdarer C, Meşe T, Tavli V. Carotid artery intima-media thickness in pediatric type 1 diabetic patients. Anadolu Kardiyol Derg 2014; 14:464-70. doi: 10.5152/akd.2014.4788.
  • Järvisalo MJ, Putto-Laurila A, Jartti L, et al. Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes 2002; 51:493-8. doi: 10.2337/diabetes.51.2.493
  • Rabago Rodriguez R, Gómez-Díaz RA, Tanus Haj J, et al. Carotid intima-media thickness in pediatric type 1 diabetic patients. Diabetes Care 2007; 30:2599-602. doi: 10.2337/dc07-0922.
  • Wang X, Huang X, Hou J. Relationship between Serum fibroblast growth factor 21 levels and morphological atherosclerotic plaque characteristics in patients with coronary heart disease. Eur Heart J Suppl 2016;18(Suppl F): F37. doi: 10.1093/eurheartj/suw036
  • Xiao Y, Liu L, Xu A, et al. Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol 2015; 14:72. doi: 10.1093/ eurheartj/suw036
  • Maahs DM, Ogden LG, Snell-Bergeon JK, et al. Determinants of serum adiponectin in persons with and without type 1 diabetes. Am J Epidemiol 2007; 166:731-40. doi: 10.1093/aje/ kwm125
  • Ljubic S, Boras J, Jazbec A, et al. Adiponectin has different mechanisms in type 1 and type 2 diabetes with C-peptide link. Clin Invest Med 2009; 32:271-9. Doi: 10.25011/cim.v32i4.6618
  • Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005; 48:1911-8. doi: 10.1007/s00125.005.1850-z.
  • Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond.) 2002; 103:137-42. doi: 10.1042/cs1030137
  • Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia. 2003; 46:459-69. doi: 10.1007/ s00125.003.1074-z
  • Hwang JS, Shin CH, Yang SW. Clinical implications of Nε- (carboxymethyl) lysine, advanced glycation end product, in children and adolescents with type 1diabetes. Diabetes Obes Metab 2005;7:263-67. doi: 10.1111/j.1463-1326.2004.00398.x

Serum fibroblast growth factor-21 levels and its relationship with carotid intima-media thickness in type 1 diabetes mellitus patients

Year 2024, Volume: 37 Issue: 1, 67 - 71, 28.01.2024

Hatice Çalışkan Mehmet Yaşar Dilek Yazıcı Oğuzhan Deyneli

https://doi.org/10.5472/marumj.1381672

Abstract

Objective: The study aimed to evaluate fibroblast growth factor-21 levels in type 1 diabetes patients and its relationship with carotid
intima-media thickness which is a marker of atherosclerosis.
Patients and Methods: We recruited 39 patients with type 1 diabetes mellitus and 39 healthy controls. Blood samples for fibroblast
growth factor-21, adiponectin and carboxymethyllysine were drawn from subjects after 8 hours fasting. Fasting blood glucose and
hemoglobinA1c levels were obtained from patient records. Carotid intima media-thickness was measured via B-mode ultrasound by
the same physician.
Results: Median fibroblast growth factor-21 levels were 0.54 (0.10-10.69) ng/ml in type 1 diabetes patients, 0.42 (0.09-1.57) ng/ml
in healthy controls (P=0.13). There was no correlation between serum fibroblast growth factor-21 levels and carotid intima-media
thickness. Carboxymethyllysine levels were similar in both groups (P=0.86). Adiponectin level was 16336.7 ± 7338.7 ng/ml in type 1
diabetes patients, 13343.1 ± 5318.7 ng/ml in control group (P=0.04).
Conclusion: Our study did not find any relation between serum fibroblast growth factor-21 levels and carotid intima-media thickness.
Further researches with wider study population are needed.

Keywords

fibroblast growth factor-21 carotid intima-media thickness type 1 diabetes mellitus

References

  • Powers, AC. Diabetes Mellitus. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison’s Principle of Internal Medicine. New York: The McGraw-Hill Companies, 2012:2968-69.
  • Fleir JS. Hormone resistance in diabetes and obesity: insulin, Leptin, and FGF21. Yale J Biol Med.Yale 2012; 85:405-14.
  • Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57:1246- 53. doi: 10.2337/db07-1476.
  • Li H, Bao Y, Xu A, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gammaglutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009; 94:2151-6. doi: 10.1210/jc.2008-2331
  • Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010; 53:934- 40. Doi: 10.1016/j.jhep.2010.05.018
  • Xiao Y, Xu A, Law LS, et al. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J Clin Endocrinol Metab 2012; 97:54-8. doi: 10.1210/jc.2011-1930
  • Zibar K, Blaslov K, Bulum T, Ćuća JK, Smirčić-Duvnjak L. Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls. Endocrine 2015; 48:848-55. doi: 10.1007/ s12020.014.0413-9
  • Yamasaki Y, Kawamori R, Matsushima H, et al. Atherosclerosis in carotid artery of young IDDM patients monitored by ultrasound high resolution B-mode imaging. Diabetes 1994; 43:634-9. doi: 10.2337/diab.43.5.634
  • Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994;236:567-73. doi: 10.1111/j.1365-2796.1994.tb00847.x.
  • Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE. Hypoadiponectimia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930-35. doi: 10.1210/ jcem.86.5.7463.
  • Imagava A, Funahashi T, Nakamura T, et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 2002;25:1665-6. doi: 10.2337/diacare.25.9.1665
  • Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23:85-9. doi: 10.1161/01. atv.000.004.8856.22331.50.
  • Stitt AW, Jenkins AJ, Cooper ME. Advanced glycation end products and diabetic complications. Informa Healthcare 2002;11:1205-23. doi: 10.1117/1.JBO.22.8.085003
  • Wautier MP, Massin P, Guillausseau PJ, et al. N(carboxymethyl) lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes and Metab 2003; 29:44–52. doi: 10.1016/s1262-3636(07)70006-x.
  • Taniguchi H, Nirengi S, Ishihara K, Sakane N. Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus. PLoS One 2022;17:e0263774. doi: 10.1371/journal.pone.0263774.
  • Zhang J, Weng W, Wang K, Lu X, Cai L, Sun J. The role of FGF21 in type 1 diabetes and its complications. Int J Biol Sci 2018;14:1000-11. doi: 10.7150/ijbs.25026.
  • Bayir O, Korkmaz HA, Dizdarer C, Meşe T, Tavli V. Carotid artery intima-media thickness in pediatric type 1 diabetic patients. Anadolu Kardiyol Derg 2014; 14:464-70. doi: 10.5152/akd.2014.4788.
  • Järvisalo MJ, Putto-Laurila A, Jartti L, et al. Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes 2002; 51:493-8. doi: 10.2337/diabetes.51.2.493
  • Rabago Rodriguez R, Gómez-Díaz RA, Tanus Haj J, et al. Carotid intima-media thickness in pediatric type 1 diabetic patients. Diabetes Care 2007; 30:2599-602. doi: 10.2337/dc07-0922.
  • Wang X, Huang X, Hou J. Relationship between Serum fibroblast growth factor 21 levels and morphological atherosclerotic plaque characteristics in patients with coronary heart disease. Eur Heart J Suppl 2016;18(Suppl F): F37. doi: 10.1093/eurheartj/suw036
  • Xiao Y, Liu L, Xu A, et al. Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol 2015; 14:72. doi: 10.1093/ eurheartj/suw036
  • Maahs DM, Ogden LG, Snell-Bergeon JK, et al. Determinants of serum adiponectin in persons with and without type 1 diabetes. Am J Epidemiol 2007; 166:731-40. doi: 10.1093/aje/ kwm125
  • Ljubic S, Boras J, Jazbec A, et al. Adiponectin has different mechanisms in type 1 and type 2 diabetes with C-peptide link. Clin Invest Med 2009; 32:271-9. Doi: 10.25011/cim.v32i4.6618
  • Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005; 48:1911-8. doi: 10.1007/s00125.005.1850-z.
  • Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond.) 2002; 103:137-42. doi: 10.1042/cs1030137
  • Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia. 2003; 46:459-69. doi: 10.1007/ s00125.003.1074-z
  • Hwang JS, Shin CH, Yang SW. Clinical implications of Nε- (carboxymethyl) lysine, advanced glycation end product, in children and adolescents with type 1diabetes. Diabetes Obes Metab 2005;7:263-67. doi: 10.1111/j.1463-1326.2004.00398.x
There are 27 citations in total.

Details

Primary Language English
Subjects Surgery (Other)
Journal Section Original Research
Authors

Hatice Çalışkan

Mehmet Yaşar

Dilek Yazıcı

Oğuzhan Deyneli

Publication Date January 28, 2024
Published in Issue Year 2024 Volume: 37 Issue: 1

Cite

APA Çalışkan, H., Yaşar, M., Yazıcı, D., Deyneli, O. (2024). Serum fibroblast growth factor-21 levels and its relationship with carotid intima-media thickness in type 1 diabetes mellitus patients. Marmara Medical Journal, 37(1), 67-71. https://doi.org/10.5472/marumj.1381672
AMA Çalışkan H, Yaşar M, Yazıcı D, Deyneli O. Serum fibroblast growth factor-21 levels and its relationship with carotid intima-media thickness in type 1 diabetes mellitus patients. Marmara Med J. January 2024;37(1):67-71. doi:10.5472/marumj.1381672
Chicago Çalışkan, Hatice, Mehmet Yaşar, Dilek Yazıcı, and Oğuzhan Deyneli. “Serum Fibroblast Growth Factor-21 Levels and Its Relationship With Carotid Intima-Media Thickness in Type 1 Diabetes Mellitus Patients”. Marmara Medical Journal 37, no. 1 (January 2024): 67-71. https://doi.org/10.5472/marumj.1381672.
EndNote Çalışkan H, Yaşar M, Yazıcı D, Deyneli O (January 1, 2024) Serum fibroblast growth factor-21 levels and its relationship with carotid intima-media thickness in type 1 diabetes mellitus patients. Marmara Medical Journal 37 1 67–71.
IEEE H. Çalışkan, M. Yaşar, D. Yazıcı, and O. Deyneli, “Serum fibroblast growth factor-21 levels and its relationship with carotid intima-media thickness in type 1 diabetes mellitus patients”, Marmara Med J, vol. 37, no. 1, pp. 67–71, 2024, doi: 10.5472/marumj.1381672.
ISNAD Çalışkan, Hatice et al. “Serum Fibroblast Growth Factor-21 Levels and Its Relationship With Carotid Intima-Media Thickness in Type 1 Diabetes Mellitus Patients”. Marmara Medical Journal 37/1 (January 2024), 67-71. https://doi.org/10.5472/marumj.1381672.
JAMA Çalışkan H, Yaşar M, Yazıcı D, Deyneli O. Serum fibroblast growth factor-21 levels and its relationship with carotid intima-media thickness in type 1 diabetes mellitus patients. Marmara Med J. 2024;37:67–71.
MLA Çalışkan, Hatice et al. “Serum Fibroblast Growth Factor-21 Levels and Its Relationship With Carotid Intima-Media Thickness in Type 1 Diabetes Mellitus Patients”. Marmara Medical Journal, vol. 37, no. 1, 2024, pp. 67-71, doi:10.5472/marumj.1381672.
Vancouver Çalışkan H, Yaşar M, Yazıcı D, Deyneli O. Serum fibroblast growth factor-21 levels and its relationship with carotid intima-media thickness in type 1 diabetes mellitus patients. Marmara Med J. 2024;37(1):67-71.
 Download Cover Image